Gold prices steady with focus on Ukraine-Russia, Jackson Hole
Pasithea Therapeutics Corp. (KTTA) stock has reached a new 52-week low, trading at $2.33. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 14.81, holding more cash than debt on its balance sheet. This latest price point reflects a significant downturn for the company, which has seen its stock value decrease by 65.11% over the past year. The decline has been particularly sharp in recent months, with a 53.21% drop over the past six months. InvestingPro analysis suggests the stock is currently trading below its Fair Value, though investors should note the company is quickly burning through cash. The 52-week low serves as a critical marker for Pasithea Therapeutics, as stakeholders consider the company's performance and future prospects. With an Altman Z-Score of 5.77 indicating financial stability, InvestingPro subscribers can access 8 additional key insights about KTTA's financial health and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.